Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 11/03/15

Roy S. Wu, PhD

Roy S. Wu, PhD

Branch Chief, CGCB

Following graduation from the University of California at Berkeley and the Albert Einstein College of Medicine, Dr. Wu was a post-doctoral fellow and Lecturer in the Department of Zoology at the University of California at Berkeley. Prior to joining the federal government in 1979, he worked for a biotech company as a Senior Scientist for 5 years. In 1986 after working for 7 years in the Laboratory of Molecular Pharmacology of the NCI's intramural program, Dr. Wu joined CTEP/NCI as the sole Program Director (Health Scientist Administrator) for the clinical grants program. Dr. Wu has been instrumental in promoting clinical research and in the twelve-fold growth of CTEP's grants portfolio since 1986. This growth resulted in the formation of the Clinical Grants and Contracts Branch in 2000.

As Chief of the Clinical Grants and Contracts Branch, Dr. Wu leads an eight member team of Program Directors, Program Analysts and Administrative Support Assistants in administering, on average, 400 active grants, contracts and cooperative agreements at an average total funded level of $400 million. The Branch plans, implements and manages two clinical research programs: Clinical Oncology and Surgical Oncology, both involved in the development and identification of new agents and methods for the treatment of cancer as well as the evaluation of combined modalities of therapy. Currently, Roy represents NCI in many capacities. Some notable examples are: the Federal Interagency Working Group on Human Stem Cell Transplantation, DHHS; Liaison with the Leukemia and Lymphoma Society of America, and Liaison with the American Society of Hematology.

Roy has an extensive bibliography (36 peer reviewed publications) including publications dealing with ribosomal RNA and ribosomal protein synthesis, reverse transcriptase inhibitors, DNA repair, the cell cycle, the ubiquitination pathway and histone variant synthesis, modification and metabolism. From 1989 to 1993, he served as the unpaid volunteer Executive Director of the Society of Chinese Bioscientists in America (SCBA). For his work and leadership he has received the following awards:

  • NIH Award of Merit 2009 for outstanding service for the redevelopment of the CTEP website to further enhance communication with and support of the oncology community
  • DHHS Hubert H. Humphrey Award For Science to America 2008 - Team Award to the National Blood Stem Cell Program Working Group for the implementation of the C. W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory
  • NIH Award of Merit 2008 for Effective Team Work that provided needed information to the Clinical Trials Working Group to make recommendations for important changes in NCI's clinical trials infrastructure
  • NCI Award 2002 for Significant Contribution to the NCI Data and Safety Monitoring Review Panel
  • NCI Award 2002 with Appreciation for Your Advice and Dedicated Service to the NCI
  • The American Society of Blood and Marrow Transplantation Public Service Award 2001
  • NIH Award of Merit 2001 for Exceptional Leadership in the Administration of a Strong and Successful Transplantation Program in Oncology
  • NCI Award 2001 with Appreciation for Dedicated Service in the Completion of the "Best Practices Document"
  • American Association for the Advancement of Science Fellow 2011
  • Ph.D. Distinguished Alumnus Award, Albert Einstein College of Medicine 2012

About the Branch Chief

Vikram Devgan, Ph.D., MBA Vikram Devgan, Ph.D., MBA. joined the National Cancer Institute in 2016 as a Chief of Clinical Grants and Contracts Branch of the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis. From 2006 to 2016, Dr. Devgan held positions of increasing responsibilities with QIAGEN Inc., rising to Head of the Center of Excellence for Biological Research Content. More…